Previous 10 | Next 10 |
35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients with ovarian, urothelial, and head & neck cancers 75% response rate in ovarian, urothelia...
2023-09-12 08:48:00 ET Summary Adaptimmune Therapeutics is a biotechnology company focused on developing cell therapies for solid tumors. Their afami-cel therapy has demonstrated signs of activity in patients with heavily pretreated sarcoma, with a 2-year rate of overall survival ...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Devel...
2023-08-09 10:18:02 ET Adaptimmune Therapeutics plc (ADAP) Q2 2023 Results Conference Call August 09, 2023 08:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late S...
2023-08-09 07:56:21 ET Adaptimmune press release ( NASDAQ: ADAP ): Q2 GAAP EPS of -$0.02 beats by $0.19 . Revenue of $5.13M (-7.4% Y/Y) misses by $1.54M . The Company believes that its existing cash, cash equivalents and marketable securities, together with the...
2023-08-08 14:26:41 ET Adaptimmune ( NASDAQ: ADAP ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is -$0.18 and the consensus Revenue Estimate is $6.67M. Over the last 1 year, ADAP has beaten EPS...
2023-08-08 10:46:10 ET Major earnings expected before the bell on Wednesday include: Brookfield Asset Management ( BAM ) 3D Systems ( DDD ) PENN Entertainment ( PENN ) Roblox ( RBLX ) Sony Group ( SONY ) For further details see: Notable ea...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US ma...
2023-06-01 17:02:47 ET Adaptimmune ( NASDAQ: ADAP ) said that it has completed its planned merger with fellow T-cell therapy developer TCR2 ( TCRR ). The immunology companies announced the merger in March. After the closing Adaptimmune shareholders own around 75% of the comb...
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded ...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...